Apimeds Pharmaceuticals US, Inc. (APUS)vsUnited Therapeutics Corporation (UTHR)
APUS
Apimeds Pharmaceuticals US, Inc.
$2.11
-3.00%
HEALTHCARE · Cap: $3.27M
UTHR
United Therapeutics Corporation
$497.11
-1.34%
HEALTHCARE · Cap: $21.36B
Smart Verdict
WallStSmart Research — data-driven comparison
UTHR leads profitability with a 41.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 61/100 (C+).
APUS
Avoid27
out of 100
Grade: F
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for APUS.
Margin of Safety
+0.8%
Fair Value
$479.95
Current Price
$497.11
$17.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : APUS
The strongest argument for APUS centers on Altman Z-Score, Debt/Equity.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : APUS
The primary concerns for APUS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
APUS profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
APUS is growing revenue faster at 0.0% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
UTHR scores higher overall (61/100 vs 27/100), backed by strong 41.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apimeds Pharmaceuticals US, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.
Visit Website →United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?